北京商报讯（记者 孔文燮）11月5日，均瑶健康发布公告称，董事长王均豪将其持有的6163万股股份进 行质押展期，占其所持股份的100%及公司总股本的10.26%。截至公告披露日，公司控股股东及其一致 行动人累计质押股份2.82亿股，占其持股比例的69.89%及公司总股本的47.00%。 ...

单位：股 证券代码：605388 证券简称：均瑶健康 公告编号：2025-060 湖北均瑶大健康饮品股份有限公司 关于董事长股份质押展期的公告 ● 公司控股股东、实际控制人及其一致行动人持有公司股份 403,853,404 股， 占公司总股本的 67.25%。控股股东、实际控制人及其一致行动人累计质押股份 数量（含本次）合计 282,244,673 股，占其持股数量比例的 69.89%，占公司总股 本的 47.00%。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次董事长股份质押展期具体情况 重要内容提示： 公司近日收到公司董事长王均豪先生的通知，获悉其将所持有本公司的部分 股份进行了股份质押展期，具体事项如下： ● 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）董事长王均豪先 生持有公司股份总数为 61,628,402 股，占公司总股本的 10.26%，质押公司股份 61,628,401 股，占其所持公司股份总数的 100.00%，占公司总股本的 10.26%。 1、截至本公告披露日，控股股东、实际控制人及其一 ...

2024年1至12月份，均瑶健康的营业收入构成为：饮料行业占比46.11%，供应链行业占比39.89%，食品 行业占比13.65%，其他业务占比0.35%。 每经AI快讯，均瑶健康（SH 605388，收盘价：7.52元）11月5日晚间发布公告称，湖北均瑶大健康饮品 股份有限公司董事长王均豪先生持有公司股份总数约为6163万股，占公司总股本的10.26%，质押公司 股份约6163万股，占其所持公司股份总数的100%，占公司总股本的10.26%。公司控股股东、实际控制 人及其一致行动人持有公司股份约4.04亿股，占公司总股本的67.25%。控股股东、实际控制人及其一致 行动人累计质押股份数量（含本次）合计约2.82亿股，占其持股数量比例的69.89%，占公司总股本的 47%。 （记者 曾健辉） 截至发稿，均瑶健康市值为45亿元。 每经头条（nbdtoutiao）——36天，美国联邦政府"停摆"创纪录！航空濒临关闭，军饷发放困难，债务 增超6000亿美元...... ...

Core Viewpoint - Junyao Health announced that Chairman Wang Junhao holds 10.26% of the company's shares and has extended the pledge of 61.6284 million shares (100% of his holdings) until December 31, 2026, with the original due date being January 3, 2025. The pledge is to provide performance guarantees for Junyao Group's debts [1] Summary by Relevant Sections - Shareholding and Pledge Details - Wang Junhao holds 10.26% of Junyao Health's shares and has pledged 61.6284 million shares, which represents 100% of his holdings [1] - The pledge has been extended to December 31, 2026, from the original due date of January 3, 2025 [1] - Financial Institutions Involved - The pledge is secured by Bank of Communications Shanghai Xuhui Branch [1] - Shareholding Structure - The controlling shareholder, actual controller, and their concerted parties hold 67.25% of the shares [1] - The total pledged shares account for 69.89% of their holdings and 47.00% of the total share capital [1] - Risk Assessment - Currently, the pledge risk is considered controllable, with no risk of forced liquidation [1]

Core Viewpoint - On October 31, Junyao Health executed a block trade of 350,000 shares, amounting to 2.247 million yuan, which represented 2.49% of the total trading volume for the day. The transaction price was 6.42 yuan, reflecting a discount of 12.89% compared to the market closing price of 7.37 yuan [1]. Summary by Categories - **Transaction Details** - The block trade involved 350,000 shares of Junyao Health at a price of 6.42 yuan per share [2]. - The total transaction value was 2.247 million yuan [1]. - The trade accounted for 2.49% of the total trading volume on that day [1]. - **Market Comparison** - The transaction price of 6.42 yuan was at a 12.89% discount to the market closing price of 7.37 yuan [1].

Market Overview - The beverage and dairy sector increased by 0.4% compared to the previous trading day, with Junyao Health leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Stock Performance - Junyao Health (605388) closed at 7.37, up 3.37% with a trading volume of 120,100 shares and a turnover of 87.84 million yuan [1] - Weiweijia (600300) closed at 3.58, up 3.17% with a trading volume of 1,225,600 shares and a turnover of 436 million yuan [1] - New Dairy (002946) closed at 17.42, up 2.41% with a trading volume of 88,900 shares and a turnover of 15.3 million yuan [1] - Other notable stocks include Panda Dairy (300898) up 1.77% and Miaokelan Duo (600882) up 1.95% [1] Capital Flow - The beverage and dairy sector saw a net inflow of 70.53 million yuan from institutional investors, while retail investors contributed a net inflow of 150 million yuan [2] - However, there was a net outflow of 221 million yuan from speculative funds [2] Individual Stock Capital Flow - Chengde Lulu (000848) had a net inflow of 49.92 million yuan from institutional investors, but a net outflow of 64.64 million yuan from speculative funds [3] - Dongpeng Beverage (605499) experienced a net inflow of 33.18 million yuan from institutional investors, with a slight outflow from speculative funds [3] - Weiweijia (600300) had a net inflow of 19.50 million yuan from institutional investors, while retail investors saw a net outflow of 20.42 million yuan [3]

Core Viewpoint - Junyao Health is a well-known company in the domestic lactic acid beverage sector, focusing on the research, production, and sales of high-quality lactic acid drinks, with advanced production processes and strict quality control systems [1] Group 1: Business Performance - In Q3 2025, Junyao Health reported revenue of 1.095 billion yuan, ranking 12th in the industry, significantly lower than the top player Yili Group at 90.341 billion yuan and second-place Bright Dairy at 18.231 billion yuan [2] - The main business composition includes probiotic beverages at 261 million yuan (34.11%), supply chain products at 261 million yuan (34.07%), probiotic foods at 168 million yuan (21.98%), and other beverages and foods at 73.183 million yuan (9.55%) [2] - The net profit for the same period was -11.3712 million yuan, ranking 14th in the industry, with a notable gap compared to Yili Group's net profit of 10.42 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Junyao Health's debt-to-asset ratio was 15.81%, lower than the previous year's 16.89% and significantly below the industry average of 41.11%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 31.18%, an increase from 29.81% in the previous year and higher than the industry average of 24.79% [3] Group 3: Executive Compensation - The chairman, Wang Junhao, received a salary of 3.1266 million yuan in 2024, a decrease of 78,100 yuan from 2023 [4] - The general manager, Yu Wei, earned a salary of 1.9935 million yuan in 2024 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 19.52% to 34,300, while the average number of circulating A-shares held per household increased by 24.25% to 17,500 [5] - Tianhong Zhongzheng Food and Beverage ETF ranked as the tenth largest circulating shareholder, holding 948,500 shares, an increase of 116,700 shares from the previous period [5]

Core Insights - Junyao Health is experiencing ongoing performance challenges during its transformation, with a decline in both revenue and net profit reported for Q3 2025 [1][2] - The company has faced a continuous drop in net profit for five consecutive years, with a reported loss of 29.12 million yuan last year [1][2] - Despite a significant increase in revenue from probiotic products, overall revenue has decreased, and the company continues to invest heavily in sales, marketing, and R&D, making it difficult to alleviate performance declines in the short term [1][3] Financial Performance - For the first three quarters of 2025, Junyao Health reported approximately 1.095 billion yuan in revenue, a year-on-year decrease of 6.95% [2] - The net profit attributable to shareholders was a loss of approximately 2.3688 million yuan, a year-on-year decline of 104.79% [2] - In Q3 alone, revenue was about 329 million yuan, down 21.9% year-on-year, with a net profit loss of approximately 9.8349 million yuan, a decline of 167.09% [2] Business Challenges - The decline in performance is attributed to reduced income and increased expenditures, leading to a decrease in total profit from the beginning of the year to the reporting period [3] - Revenue from probiotic beverages decreased by 21.35% year-on-year to 386 million yuan, with declines observed across all major regions [3] - The company faces pressure from a challenging consumer environment, a shrinking market share in the dairy beverage sector, and weak downstream customer demand [3] Strategic Initiatives - Junyao Health is focusing on optimizing its revenue structure, with new product lines showing rapid development, although this has led to increased upfront sales and marketing costs [3][5] - The company has expanded its functional strain resource library to over 50,000 strains and successfully developed low-temperature probiotic beverages [3][5] - The overseas business has seen a significant growth of 72.20% compared to the same period last year, with products now available in over 80 countries and regions [3] Market Trends - The domestic beverage market is facing challenges due to the rapid growth of freshly made tea drinks, which are replacing standardized products like dairy and probiotic beverages [4] - The decline in the probiotic beverage market is also linked to changing consumer health preferences and the fragmentation of distribution channels [4] - The international market presents a key growth opportunity for Junyao Health, particularly for probiotic beverages, although rapid growth does not guarantee profitability [4] Product Development - Junyao Health has launched new probiotic products, including low-temperature active probiotic beverages, which are positioned to enhance overall profit margins [6][7] - The company aims to leverage its probiotic business to support future beverage operations, although challenges such as high cold chain costs and inventory management remain [6][7]

Market Overview - The beverage and dairy sector experienced a decline of 0.54% on the trading day, with Junyao Health leading the drop [1] - The Shanghai Composite Index closed at 3986.9, down 0.73%, while the Shenzhen Component Index closed at 13532.13, down 1.16% [1] Stock Performance - Notable gainers in the beverage and dairy sector included: - Weiweijia (600300) with a closing price of 3.47, up 2.97% [1] - New Dairy (002946) at 17.01, up 2.47% [1] - Yili (600887) at 27.36, up 0.66% with a transaction volume of 621,200 shares and a transaction value of 1.702 billion [1] - Major decliners included: - Junyao Health (605388) at 7.13, down 3.52% [2] - Happy Home (300997) at 16.62, down 3.26% [2] - Beiyinmei (002570) at 6.28, down 2.64% with a transaction value of 305 million [2] Capital Flow - The beverage and dairy sector saw a net inflow of 193 million from institutional investors, while retail investors experienced a net outflow of 39.39 million [2] - The capital flow for key stocks showed: - Yili (600887) had a net inflow of 285 million from institutional investors, but a net outflow of 172 million from retail investors [3] - Chengde Lululemon (000848) had a net inflow of 42.62 million from institutional investors, with a net outflow of 5.37 million from retail investors [3] - Miao Ke Lan Duo (600882) had a net inflow of 20.36 million from institutional investors, but a significant net outflow of 29.61 million from retail investors [3]

Core Insights - Junyao Health reported a revenue of approximately 329 million yuan for Q3 2025, representing a year-on-year decrease of 21.91% [1] - The company recorded a net loss attributable to shareholders of approximately 18.54 million yuan, which is a year-on-year increase in loss of 213.62% [1]